FDA Requires Updated Warnings on Cardiovascular Risks for Certain Prostate Cancer Treatments

FDA Updates Labeling for GnRH Agonists With New Warnings on Diabetes and Cardiovascular Risks

The FDA took action in 2010 after it reviewed post-marketing reports on drugs that suppress testosterone for advanced prostate cancer. The agency required manufacturers to add warnings to labels for GnRH agonists about higher rates of diabetes plus cardiovascular events that included myocardial infarction, stroke and sudden cardiac death. These drugs make up a core part of androgen deprivation therapy. Multiple epidemiologic studies supported the labeling change, which appears in the Warnings and Precautions sections. [1][3]

The affected drugs include leuprolide acetate, goserelin acetate and related GnRH agonist products. [2] Prostate cancer specialists have used them for years to slow tumor growth.

Data suggest these therapies link to a 20-30 percent relative increase in cardiovascular events. [3] The National Cancer Institute document on prostate cancer treatment references the FDA labeling updates. [2] An NIH-supported review later examined the cardiovascular effects across available cohorts. [3]

Prostate cancer carries substantial mortality risk when left untreated. Government sources note that disease progression often outweighs managed side effects of therapy for patients who meet the indications. [2]

What this means

The label updates flag observed associations between these drugs and metabolic or heart-related outcomes. They draw from post-marketing reports rather than a single trial. The information highlights variations in patient risk profiles based on existing cardiovascular health.

Key takeaways

• The FDA required label updates for GnRH agonists on October 20, 2010, to include warnings on risks of diabetes, myocardial infarction, stroke and sudden cardiac death. [1]
• Leuprolide acetate, goserelin acetate and related androgen deprivation products are subject to the revised prescribing information. [2]
• Multiple studies showed a 20-30 percent relative increase in cardiovascular events among users. [3]
• GnRH agonists remain a standard component of care for advanced prostate cancer. [2]
• Labeling changes stem from observational findings linked to monitoring of glucose, lipids and blood pressure parameters. [1][3]

Limitations

Label updates are based largely on observational and epidemiologic studies rather than new randomized controlled trials. Absolute risk varies significantly by patient baseline cardiovascular health. Data on comparative safety of GnRH antagonists versus agonists continues to evolve. [3]

FAQ

Which specific androgen deprivation therapy products received the updated safety labeling?
Leuprolide acetate, goserelin acetate, and related GnRH agonist ADT products used for prostate cancer. [2]

What evidence prompted the FDA to require these label changes?
Reviews of multiple epidemiologic studies and clinical trials showed increased risks of diabetes and cardiovascular events. [1][3]

How do the cardiovascular and metabolic risks of ADT balance against benefits in prostate cancer control?
Sources indicate benefits in prostate cancer survival still outweigh risks for most indicated patients. Untreated disease progression carries higher mortality risk. [2][3]

By Helen Whitaker, Senior Editor